Patents by Inventor Jerome Deval
Jerome Deval has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230065527Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: ApplicationFiled: August 12, 2021Publication date: March 2, 2023Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Jerome Deval, Cheng Liu, Qingling Zhang
-
Publication number: 20230031213Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: ApplicationFiled: June 15, 2022Publication date: February 2, 2023Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Francois Gonzalvez, Antitsa Dimitrova Stoycheva, Cheng Liu, Jerome Deval, David McGowan
-
Publication number: 20230002413Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.Type: ApplicationFiled: May 19, 2021Publication date: January 5, 2023Inventors: Tongfei Wu, Pierre Jean-Marie Bernard Raboisson, Antitsa Dimitrova Stoycheva, Francois Gonzalvez, Jerome Deval, Cheng Liu
-
Publication number: 20220143031Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
-
Publication number: 20220144811Abstract: Disclosed herein are compounds of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
-
Publication number: 20220143032Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.Type: ApplicationFiled: November 5, 2021Publication date: May 12, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
-
Publication number: 20220112194Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 30, 2021Publication date: April 14, 2022Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing, Francois Gonzalvez
-
Publication number: 20220048922Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 28, 2021Publication date: February 17, 2022Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
-
Publication number: 20220009924Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a patient with one or more of the above compounds.Type: ApplicationFiled: July 8, 2021Publication date: January 13, 2022Applicant: ALIGOS THERAPEUTICS, INC.Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval
-
Publication number: 20210395288Abstract: Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.Type: ApplicationFiled: August 26, 2021Publication date: December 23, 2021Applicant: JANSSSEN BIOPHARMA, INC.Inventors: Leonid BEIGELMAN, Jerome DEVAL, Marija PRHAVC
-
Patent number: 11198699Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 31, 2020Date of Patent: December 14, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
-
Publication number: 20210355112Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: ApplicationFiled: May 25, 2021Publication date: November 18, 2021Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
-
Patent number: 11149049Abstract: Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.Type: GrantFiled: September 18, 2018Date of Patent: October 19, 2021Assignee: JANSSEN BIOPHARMA, INC.Inventors: Leonid Beigelman, Jerome Deval, Marija Prhavc
-
Patent number: 11091467Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: GrantFiled: May 7, 2020Date of Patent: August 17, 2021Assignee: Aligos Therapeutics, Inc.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, David McGowan, Jerome Deval
-
Publication number: 20210179656Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.Type: ApplicationFiled: February 17, 2021Publication date: June 17, 2021Applicant: Janssen BioPharma, Inc.Inventors: Leonid BEIGELMAN, Guangyi WANG, David Bernard SMITH, Jerome DEVAL, Marija PRHAVC
-
Patent number: 11021509Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.Type: GrantFiled: July 31, 2019Date of Patent: June 1, 2021Assignee: Janssen BioPharma, Inc.Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Jerome Deval, Marija Prhavc
-
Publication number: 20200354345Abstract: Disclosed herein are compounds of Formula I: TL-La-CE-HD??(I) or a pharmaceutically acceptable salt, prodrug, amide or ester thereof, where i) TL is a moiety of Formula IIa, IIb, IIIa, IIIb, IIIc, or IIId; ii) CE is a moiety of Formula IV; iii) HD is a moiety of Formula V or VI; where the substituents are as defined herein. Disclosed are also pharmaceutical compositions comprising the above compounds, and methods of treating disease by administering or contact a patient with one or more of the above compounds.Type: ApplicationFiled: May 7, 2020Publication date: November 12, 2020Applicant: ALIGOS THERAPEUTICS, INC.Inventors: Koen Vandyck, Pierre Jean-Marie Bernard RABOISSON, David McGowan, Jerome Deval
-
Publication number: 20200317686Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 31, 2020Publication date: October 8, 2020Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
-
Publication number: 20200277321Abstract: Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.Type: ApplicationFiled: September 18, 2018Publication date: September 3, 2020Inventors: Leonid BEIGELMAN, Jerome DEVAL, Marija PRHAVC
-
Patent number: RE48171Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.Type: GrantFiled: September 13, 2018Date of Patent: August 25, 2020Assignee: Janssen BioPharma, Inc.Inventors: Guangyi Wang, David Bernard Smith, Leonid Beigelman, Jerome Deval, Marija Prhavc
